Pathophysiology of Vulnerability Caused by Thrombogenic (Vulnerable) Blood

[1]  J. Badimón,et al.  Genesis and Dynamics of Atherosclerotic Lesions: Implications for Early Detection , 2009, Cerebrovascular Diseases.

[2]  Borja Ibanez,et al.  HDL-cholesterol: is it really good? Differences between apoA-I and HDL. , 2008, Biochemical pharmacology.

[3]  J. Badimón,et al.  Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease , 2008, Thrombosis and Haemostasis.

[4]  J. Hirsh,et al.  New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[5]  J. Ansell.  Factor Xa or thrombin: is factor Xa a better target? , 2007, Journal of thrombosis and haemostasis : JTH.

[6]  J. Weitz.  Factor Xa or thrombin: Is thrombin a better target? , 2007, Journal of thrombosis and haemostasis : JTH.

[7]  Y. Castier,et al.  Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. , 2007, Journal of the American College of Cardiology.

[8]  L. Kuller.  Prevention of coronary heart disease and the National Cholesterol Education Program. , 2006, Circulation.

[9]  K. Bauer.  New Anticoagulants: Anti IIa vs Anti Xa—Is One Better? , 2006, Journal of Thrombosis and Thrombolysis.

[10]  D. Harrison,et al.  Oxidant stress—a major cause of reduced endothelial nitric oxide availability in cardiovascular disease , 2006, European Journal of Clinical Pharmacology.

[11]  S. Grundy,et al.  The changing face of cardiovascular risk. , 2005, Journal of the American College of Cardiology.

[12]  Y. Arad,et al.  Objectives Background Methods Results Conclusions , 2022 .

[13]  Jackie A Cooper,et al.  A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. , 2005, Atherosclerosis.

[14]  Nigel Mackman,et al.  Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. , 2004, Blood.

[15]  J. Keaney,et al.  Role of oxidative modifications in atherosclerosis. , 2004, Physiological reviews.

[16]  V. Fuster,et al.  Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. , 2004, European heart journal.

[17]  Dong Zhao,et al.  Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. , 2004, JAMA.

[18]  I. Juhan-vague,et al.  Contribution of PAI-1 in cardiovascular pathology. , 2004, Archives des maladies du coeur et des vaisseaux.

[19]  A. Lusis,et al.  Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. , 2004, The New England journal of medicine.

[20]  P. Libby,et al.  The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach. , 2004, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[21]  V. Fuster,et al.  Caspase-3 and Tissue Factor Expression in Lipid-Rich Plaque Macrophages: Evidence for Apoptosis as Link Between Inflammation and Atherothrombosis , 2004, Circulation.

[22]  B. Furie,et al.  Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. , 2004, Trends in molecular medicine.

[23]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[24]  C. Hack,et al.  Human cell‐derived microparticles promote thrombus formation in vivo in a tissue factor‐dependent manner , 2003, Journal of thrombosis and haemostasis : JTH.

[25]  Tom Fahey,et al.  Predictive accuracy of the Framingham coronary risk score in British men:prospective cohort study , 2003, BMJ : British Medical Journal.

[26]  B. Sobel,et al.  Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[27]  M. Sata,et al.  Circulating vascular progenitor cells contribute to vascular repair, remodeling, and lesion formation. , 2003, Trends in cardiovascular medicine.

[28]  A. Hafezi-Moghadam,et al.  Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A , 2003, Nature Medicine.

[29]  N J Wald,et al.  A strategy to reduce cardiovascular disease by more than 80% , 2003, BMJ : British Medical Journal.

[30]  C. Cogbill,et al.  Preventing myocardial infarction in the young adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? , 2003, Journal of the American College of Cardiology.

[31]  W. Edwards,et al.  Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Y. Nemerson,et al.  Alternatively spliced human tissue factor: a circulating, soluble, thrombogenic protein , 2003, Nature Medicine.

[33]  V. Fuster,et al.  Role of Risk Factors in the Modulation of Tissue Factor Activity and Blood Thrombogenicity , 2003, Circulation.

[34]  V. Fuster,et al.  Pathogenetic concepts of acute coronary syndromes. , 2003, Journal of the American College of Cardiology.

[35]  Arshed A. Quyyumi,et al.  Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk , 2003 .

[36]  F. Ruschitzka,et al.  Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease , 2003, Circulation.

[37]  B. Kalyanaraman,et al.  The Role of Tetrahydrobiopterin in Superoxide Generation from eNOS: Enzymology and Physiological Implications , 2003, Free radical research.

[38]  Zaverio M. Ruggeri,et al.  Platelets in atherothrombosis , 2002, Nature Medicine.

[39]  K. Hatakeyama,et al.  Protease-activated receptor 2 (PAR2) mediates vascular smooth muscle cell migration induced by tissue factor/factor VIIa complex. , 2002, Thrombosis research.

[40]  S. Davis.  Postmenopausal hormone-replacement therapy. , 2002, New England Journal of Medicine.

[41]  K. Michaelides,et al.  Platelet membrane glycoprotein Ibα gene −5T/C Kozak sequence polymorphism as an independent risk factor for the occurrence of coronary thrombosis , 2002, Heart.

[42]  S. Yusuf,et al.  Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. , 2001, Circulation.

[43]  G. Hitman,et al.  Interaction between smoking and the glycoprotein IIIa P1(A2) polymorphism in non-ST-elevation acute coronary syndromes. , 2001, Journal of the American College of Cardiology.

[44]  P. Libby,et al.  Soluble CD40L and Cardiovascular Risk in Women , 2001, Circulation.

[45]  A. Girolami,et al.  Hemophilia A, von Willebrand Disease, and Atherosclerosis of Abdominal Aorta and Leg Arteries: Factor VIII and von Willebrand Factor Defects Appear to Protect Abdominal Aorta and Leg Arteries From Atherosclerosis , 2001, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[46]  J. Reiber,et al.  Decreased Coagulability Has No Clinically Relevant Effect on Atherogenesis: Observations in Individuals With a Hereditary Bleeding Tendency , 2001, Circulation.

[47]  R. D'Agostino,et al.  Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. , 2001, JAMA.

[48]  A. Tedgui,et al.  Current perspective on the role of apoptosis in atherothrombotic disease. , 2001, Circulation research.

[49]  J. Loscalzo.  Nitric oxide insufficiency, platelet activation, and arterial thrombosis. , 2001, Circulation research.

[50]  Valentin Fuster,et al.  Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences , 2001, Annals of Internal Medicine.

[51]  I. Penttilä,et al.  C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-α in the prognostic classification of unstable angina pectoris , 2001 .

[52]  H. Morita,et al.  Platelet protein kinase C isoform content in type 2 diabetes complicated with retinopathy and nephropathy , 2001, Platelets.

[53]  D. Harrison,et al.  Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. , 2000, Circulation research.

[54]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[55]  R. Virmani,et al.  The good smooth muscle cells in atherosclerosis , 2000, Current atherosclerosis reports.

[56]  V. Fuster,et al.  Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. , 2000, The American journal of cardiology.

[57]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[58]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[59]  N. Booth,et al.  Circulating tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in proliferative diabetic retinopathy: a pilot study , 1999, Acta Diabetologica.

[60]  G. Kojda,et al.  Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. , 1999, Cardiovascular research.

[61]  K. Channon,et al.  Nitric oxide synthase gene therapy rapidly reduces adhesion molecule expression and inflammatory cell infiltration in carotid arteries of cholesterol-fed rabbits. , 1999, Circulation.

[62]  J. Badimón,et al.  Blood-borne tissue factor: another view of thrombosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[63]  J. Freyssinet,et al.  Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. , 1999, Circulation.

[64]  K. Isaaz,et al.  Prevalence of factor V Leiden (APCR) and other inherited thrombophilias in young patients with myocardial infarction and normal coronary arteries , 1998, Heart.

[65]  A. Döring,et al.  Plasma viscosity and the risk of coronary heart disease: results from the MONICA-Augsburg Cohort Study, 1984 to 1992. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[66]  R. Ross,et al.  Atherosclerosis is an inflammatory disease. , 1998, American heart journal.

[67]  Reinhold Förster,et al.  CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells , 1998, Nature.

[68]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[69]  V. Fuster,et al.  Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. , 1997, Circulation.

[70]  J S Beckman,et al.  Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. , 1996, The American journal of physiology.

[71]  R. Virmani,et al.  Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. , 1996, Circulation.

[72]  D. Harrison.  Endothelial control of vasomotion and nitric oxide production: a potential target for risk factor management. , 1996, Cardiology clinics.

[73]  T. Warkentin.  Hemostasis and atherosclerosis. , 1995, Canadian Journal of Cardiology.

[74]  D. Ardissino,et al.  Persistent Activation of Coagulation Mechanism in Unstable Angina and Myocardial Infarction , 1994, Circulation.

[75]  S. S. Hull,et al.  Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. , 1991, Circulation research.

[76]  M. Benezra,et al.  Thrombin immobilized to extracellular matrix is a potent mitogen for vascular smooth muscle cells: nonenzymatic mode of action. , 1990, Cell regulation.

[77]  C. Zarins,et al.  Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.

[78]  P. Schwartz,et al.  The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity. , 1985, American heart journal.

[79]  C. Forbes,et al.  Plasma Fibrinopeptide A and Beta-Thromboglobulin in Patients with Chest Pain , 1983, Thrombosis and Haemostasis.

[80]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[81]  J. Manson,et al.  Postmenopausal hormone replacement therapy. Authors' reply , 2002 .

[82]  A. Silveira.  Postprandial triglycerides and blood coagulation. , 2001, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.